anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Socioeconomic status (SES) has been proven to be associated with chronic obstructive pulmonary disease (COPD) in Western populations, but the evidence is very limited in China. This study aimed to investigate the association between SES and the risk of COPD incident.
METHODS: This study was based on the China Kadoorie Biobank (CKB) project in Wuzhong District, Suzhou. A total of 45,484 adults aged 30-79 were included in the analysis during 2004-2008. We used Cox proportional hazard models to investigate the association between SES and the risk of COPD. Household income, education, private property and consumption potential was used to measure SES. Incident COPD cases were ascertained using hospitalization records, death certificates, and active follow-up.
RESULTS: A total of 524 COPD cases were identified during a median follow-up of 11.2 years. Household income was inversely associated with the risk of COPD (Ptrend<0.005). The adjusted hazard ratios (95% confidence intervals) for incident COPD were 0.88 (0.69-1.14), 0.77 (0.60-0.99), and 0.42 (0.31-0.57) for participants with annual household income of 10,000 ~ 19,999 yuan, 20,000 ~ 34,999 yuan and ≥ 35,000 yuan respectively, in comparison to participants with an annual household income < 10,000 yuan. Furthermore, we found that education level, refrigerator use, private toilet, private phone, and motor vehicle were adversely associated with COPD risk, while ownership of newly renovated flats was positively correlated with COPD incident.
CONCLUSIONS: This prospective study suggests that SES is associated with the risk of COPD in Chinese adults. Population-based COPD prevention strategies tailored for people with different SES could help reduce the burden of COPD in Chinese.
General: Topical metronidazole has been reported to cause tearing of the eyes. Therefore, contact with the eyes should be avoided. If a reaction suggesting local irritation occurs, patients should be directed to use the medication less frequently or discontinue use. Metronidazole is a nitroimidazole and should be used with care in patients with evidence of, or history of blood dyscrasia.

Information for patients: This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.

Drug interactions: Oral metronidazole has been reported to potentiate the anticoagulant effect of warfarin and coumarin anticoagulants, resulting in a prolongation of prothrombin time. The effect of topical metronidazole on prothrombin time is not known.

Carcinogenesis, mutagenesis, impairment of fertility: Metronidazole has shown evidence of carcinogenic activity in a number of studies involving chronic, oral administration in mice and rats but not in studies involving hamsters.

Metronidazole has shown evidence of mutagenic activity in several in vitro bacterial assay systems. In addition, a dose-response increase in the frequency of micronuclei was observed in mice after intraperitoneal injections and an increase in chromosome aberrations have been reported in patients with Crohn's disease who were treated with 200-1200 mg/day of metronidazole for 1 to 24 months. However, no excess chromosomal aberrations in circulating human lymphocytes have been observed in patients treated for 8 months.

Pregnancy:Teratogenic effects: Pregnancy category B

There are no adequate and well-controlled studies with the use of metronidazole topical cream in pregnant women. Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. No fetotoxicity was observed after oral metronidazole in rats or mice. However, because animal reproduction studies are not always predictive of human response and since oral metronidazole has been shown to be a carcinogen in some rodents, this drug should be used during pregnancy only if clearly needed.

Nursing mothers: After oral administration, metronidazole is secreted in breast milk in concentrations similar to those found in the plasma. Even though blood levels are significantly lower with topically applied metronidazole than those achieved after oral administration of metronidazole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric use: Safety and effectiveness in pediatric patients have not been established.
The experimental intervention is the installation of a dynamic LED-light system in 10 separate patient single rooms. The system includes three elements: a window jamb built-in light panel, two ceiling mounted lamps, and a wall mounted lamp. All lamps will have a dynamic, time dependent frequency distribution and intensity of light.
This is a clinical study involving patients undergoing orthodontic treatment with fixed appliances ('train-track braces'). A new type of train-track has recently been marketed. Over 4 million patients worldwide are wearing on of these appliances; this system is considerably more expensive than a normal train-track. However, there is little evidence to support its use.

The effects of three different types of train-track will be assessed in this clinical trial with respect to the quality of Orthodontic tooth movement produced. Furthermore, the impact of the different train-tracks on daily life of orthodontic patients will also be measured. Consequently, the investigators will be able to inform orthodontists' decisions relating to the choice of train-track they recommend for their patients. In addition, should the more expensive appliances demonstrate objective or subjective advantage, a significant efficiency saving may develop.
PURPOSE:A skin remedying solution obtained by adding garlic, and aloe, etc., to vinegar, and boiling the blend under heating. CONSTITUTION:Vinegar is blended with garlic and aloe, etc., heated, boiled, medicinal components such as garlic, aloe, etc. are dissolved and retained in the vinegar, to give a skin remedying solution. When the solution is used, it is reheated, kept at about 50 deg.C, the skin is immersed in it, the affected part is dipped in the solution at a proper temperature. When the affected part of the skin is dipped in the solution at high temperature, it is swollen up, the medicinal components of the solution are permeated into the affected part. The affected part of the skin is dipped in the solution twice a day for about 10-15min, the skin is peeled off and made clean in about 10 days, and the affected part is remedied. Oral administration can also promote remedy of the affected part of the skin. EFFECT:The skin is remediea only with the solution by dipping the affected part in the solution, the solution may be orally administered, and internal organs can be remedied completely in a short period.
Sixteen subjects will receive 3 mg Midazolam once by mouth on Day 1. On Days 3-12, subjects will receive FTX-6058 by mouth once daily. On Day 12, a second dose of 3 mg Midazolam will be given once by mouth. The dose of FTX-6058 will be the highest tolerated dose from Part B.
FIELD: organic compounds. SUBSTANCE: proposed composition contains (mass %): destructurized starch 50-99, hydrolyzed copolymer of vinylacetate and ethylene, propylene, isobutylene or styrene 1-50. Humidity of said composition is 5-40 %. Processing of said composition is carried out by heating mixture of mentioned above components in sealed volume till homogeneous melt is prepared. Then formation in common way is carried out. Said heating and formation take places at humidity 5-40 %. Melt of said composition is prepared by heating mixture of mentioned above components in sealed volume till homogeneous melt which contains completely destructurized starch is prepared. EFFECT: improves quality of desired composition, improves its processing. 6 cl, 4 tbl
BACKGROUND: Fibroblast differentiation to a myofibroblast phenotype is a feature of airway remodeling in asthma. Lung fibroblasts express the integrin receptor α4β7 and fibronectin induces myofibroblast differentiation via this receptor.
OBJECTIVES: To investigate the role of the β7 integrin receptor subunit and α4β7 integrin complex in airway remodeling and airway hyperresponsiveness (AHR) in a murine model of chronic allergen exposure.
METHODS: C57BL/6 wild type (WT) and β7 integrin null mice (β7 -/-) were sensitized (days 1,10) and challenged with ovalbumin (OVA) three times a week for one or 4 weeks. Similar experiments were performed with WT mice in the presence or absence of α4β7 blocking antibodies. Bronchoalveolar (BAL) cell counts, AHR, histological evaluation, soluble collagen content, Transforming growth factor-β (TGFβ) and Interleukin-13 (IL13) were measured. Phenotype of fibroblasts cultured from WT and β7 -/- saline (SAL) and OVA treated mice was evaluated.
RESULTS: Eosinophil numbers were similar in WT vs β7-/- mice. Prolonged OVA exposure in β7-/- mice was associated with reduced AHR, lung collagen content, peribronchial smooth muscle, lung tissue TGFβ and IL13 expression as compared to WT. Similar findings were observed in WT mice treated with α4β7 blocking antibodies. Fibroblast migration was enhanced in response to OVA in WT but not β7 -/- fibroblasts. α-SMA and fibronectin expression were reduced in β7-/- fibroblasts relative to WT.
CONCLUSIONS: The β7 integrin subunit and the α4β7 integrin complex modulate AHR and airway remodeling in a murine model of allergen exposure. This effect is, at least in part, explained by inhibition of fibroblast activation and is independent of eosinophilic inflammation.
Atropine

Atropine competitively blocks the effects of acetylcholine, including excess acetylcholine due to organophosphorus nerve agent poisoning, at muscarinic cholinergic receptors on smooth muscle, cardiac muscle, secretory gland cells, and in peripheral autonomic ganglia and the central nervous system.

Pralidoxime Chloride

Pralidoxime chloride reactivates acetylcholinesterase which has been inactivated by phosphorylation due to susceptible organophosphorus nerve agents having anticholinesterase activity . However, pralidoxime chloride does not reactivate acetylcholinesterase inactivated by all organophosphorus nerve agents (e.g. soman). Pralidoxime chloride cannot reactivate phosphorylated acetylcholinesterases that have undergone a further chemical reaction known as "aging." Reactivated acetylcholinesterase hydrolyzes excess acetylcholine resulting from organophosphorus nerve agent poisoning to help restore impaired cholinergic neural function. Reactivation is clinically important because only a small proportion of active acetylcholinesterase is needed to maintain vital functions.
Currently used techniques for sealing impaired tissue following medical procedures are not optimal. Manual compression, though effective, is time consuming and current sealing products use animal proteins, which can cause immunological reactions and disease. Therefore, a desirable product is one that easily and effectively seals a wound in tissue without side effects. Lipids that adhere to tissue and expand in size when applied are well suited for use as a biosealant device. Lipids, which are solid at sub-physiological temperature and exhibit a phase change at or about physiological temperature to adhere and expand within the wound are desirable for use in a biosealant device. One such class of lipid that is naturally well suited for this use are cubic phase forming monoglycerides. However, other lipids in their natural or modified states can also be used.
The method involves registering information related to a patient in forms, which are stored in a data memory of a computer. Chores already performed at the patient are registered in chore-related forms. The information registered in the forms is automatically accessed by a function stored on the computer. Chores still to be performed are selectively displayed by display elements, which are represented on a monitor of the computer. The display elements are associated to each type of the chores. Independent claims are also included for the following: (1) a computer program product comprising instructions for performing a method for selectively presenting information contained in a patient dossier (2) a computer.
Our previous case-control study (protocol #01-I-N020) established that hemoglobin (Hb) C protects against severe malaria in the Dogon ethnic group of Mali, West Africa. We believe that abnormal display of major parasite virulence antigens (PfEMP-1) on the surface of HbC erythrocytes accounts for this protection. Whether this mechanism mediates protection by other mutant erythrocytes remains to be investigated. The principal objective of the current protocol has been to investigate whether HbC also protects against severe malaria in the Malinke of Kela, which historically gave rise to the Dogon. Our preliminary data from protocol #02-I-N285 suggest that HbC but not HbS (sickle trait) protects the young Malinke children of Kela, with the opposite being true for the Malinke children of Kangaba, a nearby village. To confirm these novel preliminary findings and to investigate candidate mechanisms of protection, our ongoing case-control study requires an additional 150 severe malaria patients who are less than 5 years old, of Malinke ethnicity, reside in either Kangaba or Kela villages, and have normal G6PD activity. Children less than 11 years old and diagnosed with either severe (case) or uncomplicated (control) malaria will be tested for hemoglobinopathies and G6PD deficiency. Severe and uncomplicated malaria patients will be treated with parenteral quinine or oral artemisinin combination therapies, respectively, which are standard of care in Mali. Principal outcome measures will include a comparison of the frequency of HbC, HbS, and G6PD deficiency between cases and controls; with odds ratios and 95% confidence intervals determining the degree and statistical significance of severe malaria protection.
The present invention is in the field of processes for making alkylbenzenesulfonate surfactants. The processes herein include a combination of two essential steps, delinearization and alkylation. The delinearization step selected herein introduces particular types of limited branching into an aliphatic hydrocarbon having ten or more, but no more than about 16, carbon atoms. The hydrocarbon includes olefin having a hydrocarbon chain length suitable for detergent manufacture, e.g., C10-C14, or a corresponding paraffin. The second essential step is an alkylation step having an internal isomer selectivity of from 0 to no more than about 40 in which the hydrocarbon is used to monoalkylate benzene catalytically with an alkylation catalyst. Such alkylation catalysts preferably comprise an at least partially crystalline porous zeolite-containing solid, the zeolite having moderate acidity and intermediate pore size. Preferred alkylation catalysts include certain at least partially dealuminized acidic nonfluorinated mordenites. The processes herein further comprise sulfonating, neutralizing and incorporating the resulting modified alkylbenzenesulfonate surfactants into consumer products. The invention relates also to the products of the processes, including modified surfactants and consumer cleaning products containing them.
Increases in serum transaminases have occurred with Altoprev [see Adverse Reactions (6.1)]. In most cases, these changes appeared soon after initiation, were transient, were not accompanied by symptoms, and resolved or improved on continued therapy or after a brief interruption in therapy. Persistent increases to more than three times the upper limit of normal (ULN) in serum transaminases have occurred in approximately 1.9% of patients receiving Altoprev in clinical studies. Marked persistent increases of hepatic transaminases have also occurred with Altoprev. There have been rare post marketing reports of fatal and non-fatal hepatic failure in patients taking statins, including Altoprev. 

Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.

Consider liver enzyme testing before Altoprev initiation and when clinically indicated thereafter. Altoprev is contraindicated in patients with acute liver failure or decompensated cirrhosis [see Contraindications (4)]. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue Altoprev.
The present invention relates to a composition for the treatment of senile sarcopenia containing an Actn3 inhibitor as an active ingredient. Age-related sarcopenia is a condition in which there is a loss of muscle mass and function resulting in a decrease in mobility and exercise capacity with advancing age. However, little is known about the mechanisms by which muscle changes with age. In this study, it is shown that Mind bomb-1 (Mib1) plays an important role in maintaining skeletal muscle through the degradation of α-actinin 3 (Actn3) according to age. Mib1 deficiency in muscle fibers causes Actn3 to accumulate, leading to changes in type 2 glycolytic myofibers, muscle atrophy, and decreased muscle function. Mice with Mib1 deletion in muscle fibers showed muscle atrophy after exercise. However, chronic exercise-induced muscle atrophy was ameliorated when Actn3 expression was reduced. Importantly, the expression of Mib1 and Actn3 changes with age and with a decrease in skeletal muscle function, demonstrating the clinical efficacy of Mib1 and Actn3 in sarcopenia.
PURPOSE:To obtain a cosmetic capable of exhibiting sufficient adhesive strength, by bonding muddy or clayey powdery cosmetic dispersed in a solvent to a supporting tool having water . oil absorbing property and air permeability using permeation of the solvent into the supporting tool or suction by a vacuum pump, etc. CONSTITUTION:A muddy clayey powdery cosmetic consisting of cosmetic powder (e.g. talc, mica, ultramarine, nylon powder, organic coloring matter or pigment), a solvent (e.g. water, alcohol, hydrocarbon, silicone oil or squalane) and a binder (e.g. carboxymethyl cellulose or magnesium aluminum silicate) is bonded to a supporting tool (e.g. paper, cotton or biscuit plate) having water . oil absorbing property and air permeability by permeating the solvent into the supporting tool or sucking the cosmetic from the side opposite to the adhesive surface and bonding to the binder with a sufficient strength. Thereby a molded product having a novel shape is obtained. A method for bonding the cosmetic to a hollow supporting rod 1 with an absorbent cotton 2 is shown in the figure (4 is the cosmetic and 3 communicates with a vacuum pump).
The invention provides a drug for treating or preventing drug-resistant relapse of acute lymphoblastic leukemia (ALL) and application thereof. The drug acts on enzymes generated in the purine synthetic route, and the probability of drug-resistant relapse of ALL is lowered by lowering the concentration of hypoxanthine. The invention further provides application of the compound Lometrexol and relevant targeted GART and ATIC preparations to preparation of the drug for preventing or treating drug-resistant relapse of ALL. The invention further provides a kit for evaluating the drug-resistant relapse risk of ALL and an application method of the kit. The kit comprises a reagent for splitting of sample cells. The application method comprises the steps that 1, the sample cells are collected and split; 2, the content of hypoxanthine, IMP, AICAR and inosine is detected; 3, the drug-resistant relapse risk of ALL of the samples is judged. The drug provides a powerful technical means and support for prevention and treatment of drug-resistant relapse of ALL.
OBJECTIVE: To assess the effect of platycodin D (PD) for alleviating pulmonary fibrosis in mice and explore the underlying mechanism.
METHODS: C57BL/6J mouse models of pulmonary fibrosis induced by bleomycin injection into the airway were treated with daily intragastric administration of 10 mg/kg PD for 28 days. The changes of pulmonary fibrosis and the expression and distribution of transient receptor potential cation channel subfamily C member 6 (TRPC6) were evaluated with immunohistochemistry, HE staining and Sirius Red staining. Western blotting was used to detect α-SMA expression in the lung tissues of the mice. Primary cultures of mouse lung fibroblasts were pretreated with PD (2.5, 5.0, and 10 μmol/L) or larixyl acetate (LA; 10 μmol/L) before exposure to 10 ng/mL transforming growth factor-β1 (TGF-β1), and the changes in cell survival rate, expressions of collagen Ⅰ, α-SMA and TRPC6, reactive oxygen species (ROS) production, mitochondrial membrane potential, and cell proliferation capacity were assessed. Network pharmacology analysis was performed to explore the mechanism by which PD alleviated pulmonary fibrosis.
RESULTS: PD treatment significantly alleviated pulmonary fibrosis and reduced α-SMA expression in BLM-induced mouse models (P<0.05). In TGF-β1-induced primary mouse lung fibroblasts, PD effectively inhibited the cell proliferation, reduced ROS production (P<0.0001), rescued the reduction of mitochondrial membrane potential (P<0.001), and inhibited the expressions of α-SMA and collagen Ⅰ (P<0.05). Network pharmacology analysis suggested that TRPC6 mediated the effect of PD for alleviating pulmonary fibrosis. Immunohistochemistry showed that PD significantly reduced TRPC6 expression in the lung tissues of BLM-induced mice. In primary mouse lung fibroblasts, PD significantly inhibited TGF-β1-induced TRPC6 expression (P<0.05), and LA treatment obviously lowered the expression levels of TRPC6, α-SMA and collagenⅠ (P<0.05).
CONCLUSION: PD alleviated pulmonary fibrosis in mice possibly by down-regulating TRPC6 and reducing ROS production.
553,587. Heating plasters; external medicines. SROKA, C. B. Jan. 27, 1942, No. 1109. [Classes 81 (i) and 81 (ii)] A therapeutic plastic pad capable of receiving and transmitting heat is combined with a heater pad comprising substances which develop heat by chemical action on being moistened with water or other suitable solutions and so heats or maintains the heat of the plastic pad; the heater pad may be separable from the plastic pad and may comprise a sheet of absorbent material impregnated with a solution of a reagent and subsequently dried, a sheet of aluminium foil, and a cover of impervious material. The reagent may be bichloride of mercury or copperchloride which when moistened with peroxide of hydrogen and brought into contact with the aluminium generates the heat. The plastic pad may comprise a mixture of kaolin, boric acid, methyl salicylate, thymol, glycerine, oil of peppermint to which may be added paraffin and other suitable. oils.
FIELD: medicine, pharmacy, antibiotics. SUBSTANCE: water-soluble conjugate or its salt has polymixin B or its salt and dextran. It shows an anti-endotoxic activity that exceeds that of the parent polymixin B. The ratio of polymixin B IC 50  value to its conjugate IC 50  value is above 1.0. Invention claims the method of conjugate preparing. Polymixin B or its salt is subjected for interaction with dextran in an aqueous medium at pH from 9.3 to 10 and temperature from 30 C to 35 C. Invention claims the composition containing water-soluble conjugate. Conjugate has the enhanced anti-endotoxic activity and method exhibits the best reproducibility. Conjugate activity is 125% and above as compared with that of the natural polymixin B. Invention can be used for preparing preparations used in therapy of systemic inflammatory reaction syndrome and septic shock. EFFECT: enhanced effectiveness of conjugates. 13 cl, 3 tbl, 5 ex